as of 11-13-2026 3:51pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | 248 | City: | AMSTERDAM |
| Market Cap: | 3.1B | IPO Year: | 2013 |
| Target Price: | $59.78 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.95 | EPS Growth: | 29.67 |
| 52 Week Low/High: | $8.73 - $51.72 | Next Earning Date: | 11-04-2026 |
| Revenue: | $13,107,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 44.21% | Revenue Growth (next year): | 398.45% |
| P/E Ratio: | -8.41 | Index: | N/A |
| Free Cash Flow: | -178402000.0 | FCF Growth: | N/A |
Director
Avg Cost/Share
$21.25
Shares
9,080
Total Value
$192,950.00
Owned After
30,667
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Meek David D. | QURE | Director | Nov 6, 2026 | Sell | $21.25 | 9,080 | $192,950.00 | 30,667 |
SEC 8-K filings with transcript text
Nov 4, 2026 · 100% conf.
1D
+5.76%
$24.36
Act: -7.08%
5D
+17.22%
$26.99
20D
+13.87%
$26.22
2 tm2628930d1_ex99-1.htm
Exhibit 99.1
uniQure Announces Third Quarter 2026 Financial Results and
Provides Company Update
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~
~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~
~ Cash, cash equivalents and investment securities of approximately $768.4 million as of September 30, 2026 expected to fund operations into 2030 ~
~ uniQure to host earnings call at 8:30 a.m. ET ~
Lexington, MA and Amsterdam, the Netherlands, November 4, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2026 and highlighted recent progress across its business.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease,” said Matthew Kapusta, chief executive officer at uniQure. “We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
"As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,” Mr. Kapusta continued. “We are grateful to the patients, families and investigators who have made this progress possible, and are honored to continue to work alongside this community."
Recent Company Developments and Updates
Advancing ifezuntirgene inilparvovec towards potential accelerated approval for the treatment of Huntington’s disease
·In November 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Company’s Biologics License Application (BLA) for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway. The BLA was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.
·In September 2026, the Company announced additional data from its ongoing Phase I/II studies with a data cutoff of June 30, 2026.
oIn the 12 high-dose patients with 48 months of follow-up, composite Unified Huntington’s Rating Scale (cUHDRS), the pre-specified primary endpoint for the analysis, showed a 44% slowing of disease progression versus the updated external control (non-significant p=0.144). Total Functional Capacity (TFC), the primary measure for the confirmatory study, showed a 61% slowing (nominal p=0.008) at 48 months. At 48-months, high-dose patients compared to low-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC, consistent with a dose-dependent treatment effect. Cerebrospinal fluid neurofilament light chain (NfL) remained near baseline at 48 months.
oAn updated 36-month analysis including all 15 high-dose patients showed an 80% slowing on cUHDRS (nominal p=0.005) and a 67% slowing on TFC (nominal p=0.011).
oIfezuntirgene inilparvovec was generally well tolerated with a manageable safety profile across 51 total treated patients.
·The Company and the FDA reached alignment on key elements of the confirmatory study of ifezuntirgene inilparvovec. The study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months. The Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.
·In the third quarter of 2026, the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorization Application (MAA) for ifezuntirgene inilparvovec, which was submitted to the MHRA earlier in the quarter.
·The Company continues to advance its launch readiness activities, including the build out of its field medical, market access, and strategic account teams as well as engagement with U.S. Huntington’s disease treatment centers.
Continued clinical progress in pipeline programs
AMT-260 for the treatment of refractory mesial
temporal lobe epilepsy (MTLE)
·In the third quarter of 2026, the Company completed enrollment in the second dose cohort of seven patients in the ongoing Phase I/IIa study and expects to present updated results in the first half of 2027.
AMT-191 for the treatment of Fabry disease
·In August 2026, enrollment resumed in the mid- and high-dose cohorts of the ongoing Phase I/
Jul 29, 2026 · 100% conf.
1D
+5.81%
$42.40
Act: +5.29%
5D
+17.97%
$47.27
20D
+12.39%
$45.03
2 qure-20260729xex99d1.htm
Exhibit 99.1
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~
~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~
~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~
~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~
~ uniQure to host earnings call at 8:30 a.m. ET ~
Lexington, MA and Amsterdam, the Netherlands, July 29, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2026 and highlighted recent progress across its business.
“This has been a defining quarter – not just for uniQure, but for the Huntington's disease community,” said Matthew Kapusta, chief executive officer at uniQure. “Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease. With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it.”
“Beyond AMT-130, we continue to execute across our broader pipeline,” Mr. Kapusta continued. “With a strong balance sheet, we believe we are well-positioned for what will be a transformative period for uniQure and the patients we serve.”
Recent Company Developments and Updates
Advancing AMT-130 for the treatment of Huntington’s disease
●In June 2026, the Company held a Type B meeting with the U.S. Food and Drug Administration (FDA). Official meeting minutes received in July 2026 confirmed that the FDA and the Company reached alignment that a Biologics License Application (BLA) submission under the accelerated approval pathway for AMT-130, based on the existing clinical data, is reasonable. In addition, the FDA seeks to align on the confirmatory study design prior to the BLA submission, including consideration of a randomized standard-of-care control design instead of a sham procedure. The FDA also stated that, in accordance with the FDA’s draft public guidance for accelerated approvals, the confirmatory study should be feasible to conduct within a reasonable timeline and be well underway, and potentially fully enrolled, at the time of accelerated approval.
●Discussions with the FDA to align on the confirmatory study design and analysis are underway and the Company expects to submit a BLA in the third quarter of 2026. The Company plans to initiate the confirmatory study as expeditiously as possible after aligning with the FDA on the trial design.
●In September 2026, the Company plans to present data from its ongoing Phase I/II studies of AMT-130. The update is expected to include follow-up data on all patients treated with AMT-130 in the first two cohorts, including four years of follow-up on 24 patients (12 patients at the high-dose and 12 patients at the low dose).
●In March 2026, the Company held a successful pre-submission meeting with the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) and the regulatory submission is progressing as planned for the third quarter of 2026.
Continued clinical progress in pipeline programs
AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)
●In June 2026, the Company announced preliminary six-month follow-up data on the first, low dose cohort of six patients in the ongoing Phase I/IIa study.
oAs of the May 29, 2026 data cutoff date, three of six patients in the first, low-dose cohort achieved meaningful reductions in disabling seizures during months four through six of follow-up, ranging from a 79% to 100% decline from baseline. The remaining three patients in the low-dose cohort experienced variable changes in disabling seizures during months four through six of follow-up, ranging from a 33% decrease to a 36% increase compared to baseline.
oAs of the June 19, 2026 presentation date, there were no Serious Adverse Events (SAEs) related to AMT-260 or the surgical procedure reported. All reported adverse events in the low dose cohort were classified as mild or moderate in severity, with the most common adverse event being headache (N=2). No immunosuppression was required.
●The Company expects t
May 5, 2026 · 100% conf.
1D
+5.56%
$22.34
Act: +7.84%
5D
+15.53%
$24.45
Act: +37.52%
20D
+8.73%
$23.01
Act: +41.68%
2 qure-20260505xex99d1.htm
Exhibit 99.1
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA~
~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~
~ Presented updated data from AMT-191 Phase I/IIa in Fabry disease study showed sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels; subsequently all 11 dosed patients have discontinued enzyme replacement therapy ~
~ Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029 ~
~ uniQure to host earnings call at 8:30 a.m. ET ~
Lexington, MA and Amsterdam, the Netherlands, May 5, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.
“During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader pipeline,” said Matthew Kapusta, chief executive officer at uniQure. “We believe our data continue to support the potential for AMT-130 to fundamentally change the treatment landscape for Huntington’s disease, and we look forward to continued engagement with the FDA. In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international opportunities.”
“We expect to deliver key clinical updates throughout 2026, including data from our AMT-260 program in refractory mesial temporal lobe epilepsy later in the second quarter and four-year AMT-130 data analysis in the third quarter,” Mr. Kapusta continued. “With these important milestones ahead, we remain committed to advancing our programs with urgency while maintaining disciplined capital allocation to drive long-term shareholder value.”
Recent Company Developments and Updates
Advancing AMT-130 for the treatment of Huntington’s disease
●The Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) in January 2026 to discuss the regulatory path forward following an October 2025 pre-Biologics License Application (BLA) meeting. Following receipt of final meeting minutes from the Type A meeting, the Company announced that the FDA stated it cannot agree that data from the Phase
I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130.
●The Company has been granted a Type B meeting with the FDA and plans to discuss key elements of a potential new clinical trial design and to solicit feedback on the proposed statistical analysis plan for the four-year data expected in the third quarter of 2026.
●Following a constructive pre-submission meeting with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA), the Company expects to submit a Marketing Authorization Application (MAA) for AMT-130 based on three-year data in the third quarter of 2026.
Continued clinical progress in pipeline programs
AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)
●In 2025, the Company completed enrollment in the first dose cohort of six patients in the Phase I/IIa study. Enrollment is ongoing in a second dose cohort, expected to include an additional six patients. Enrollment of the second cohort is expected to be completed in mid-2026.
●The Company expects to provide data from the first cohort of six patients in the Phase I/IIa study with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference, June 18 -19, 2026.
AMT-191 for the treatment of Fabry disease
●In February 2026, the Company presented updated safety and exploratory efficacy data from the Phase I/II study of AMT-191 in Fabry disease (data cutoff as of January 8, 2026):
oDose-dependent elevations were observed across 11 patients in three dose levels with α-Gal A activity ranging from 0.34- to 82.2-fold above mean normal range1 at the lowest dose, 1.6- to 312.5-fold at the mid dose, and 27.7- to 223.7-fold at the highest dose. These increases were durable across follow-up periods ranging from four months to more than one year.
oPlasma lyso-Gb3 levels were stable post-dose across all cohorts, regardless of enzyme replacement therapy (ERT) status.
●As of February 18, 2026, all 11 dosed patients were withdr
See how QURE stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.